Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.

DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.

The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable...

For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.

Cerbios has appointed Francesca Scarpitta as director of the company’s high potency active ingredients (HPAIs) production units.

Lugano, Switzerland-based chemical and biological API manufacturer Cerbios announced that its board of directors has approved the installation of a new production line in...